Your shopping cart is currently empty

YZL-51N is a selective SIRT7 inhibitor with an IC50 of 12.71 μM. It disrupts the activity of the SIRT7 enzyme by occupying the NAD+ binding pocket, which diminishes DNA damage repair and inhibits cancer cell survival. Due to its antitumor activity, YZL-51N is employed in cancer research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | YZL-51N is a selective SIRT7 inhibitor with an IC50 of 12.71 μM. It disrupts the activity of the SIRT7 enzyme by occupying the NAD+ binding pocket, which diminishes DNA damage repair and inhibits cancer cell survival. Due to its antitumor activity, YZL-51N is employed in cancer research. |
| Targets&IC50 | SIRT7:12.71 μM |
| In vitro | YZL-51N (0-40 μM, 8 h) demonstrates a dose-dependent increase in H3K18ac levels in HCT116 and HT29 cells. |
| In vivo | YZL-51N (15 mg/kg, subcutaneous injection) effectively reduces tumor volume in the HCT116 xenograft model. |
| Molecular Weight | 330.29 |
| Formula | C17H14O7 |
| Cas No. | 3031072-69-9 |
| Smiles | C(=C\C(=O)C1=CC(O)=C(O)C=C1)(\C(OC)=O)/C2=CC(O)=C(O)C=C2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.